United States-based Parnell Pharmaceuticals has announced that it has developed Nomovid, claimed to be the first antiviral nasal spray in the United States, it was reported on Wednesday.
The company says that the product is easy-to-use, low-cost and can be offered over-the-counter for consumers.
The product is based on a substance licensed by the company from New Mexico Tech University to treat drug-resistant bacteria and fungi such as MRSA and Candida auris. Parnell had been taking the necessary steps to enter the FDA approval process for the MRSA indication, until it reportedly saw very positive results against COVID-19. The company is now filing for the COVID-19 indication instead.
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion